On June 17, Korea Investment & Securities recognized Celloid as a potential game changer in the organoid market. Celloid is gaining significant attention for its innovative solutions.

The organoid industry is poised for rapid growth, driven by the expansion of the advanced regenerative medicine sector and regulatory shifts such as the U.S. FDA’s phased elimination of animal testing. Demand for organoids is rising as they become essential platforms for developing and validating regenerative therapies, and their adoption is expected to grow as a reliable alternative to animal testing.

With its proprietary technology enabling the stable production of high-quality organoids, Celloid is positioned to be a key player in this expanding market.

Go to link